Moreover, CSF analysis provides indirect, non-quantitative evidence of amyloid deposits in the brain. Method number 2 involves a technique for imaging the brain called positron emission tomography ...
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
GlobalData on MSN1d
Alector stock drops after Alzheimer’s drug fails in Phase II trialThe therapy failed to slow disease progression in patients with early Alzheimer’s in the INVOKE-2 trial (NCT04592874).
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...
New screening data reported from ongoing and past trials indicated that, across racial and ethnic groups, blood biomarkers were faithful predictors of amyloid plaques lurking in the brain. However, in ...
The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...
To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback